Cancer Biologics Market
According to Intent Market Research, the Cancer Biologics Market is expected to grow from USD 87.1 billion in 2023 at a CAGR of 9.5% to touch USD 164.9 billion by 2030. The Cancer Biologics Market is dominated by key players such as Amgen, Bristol-Myers Squibb, Roche, Merck & Co., Novartis, Johnson & Johnson, Eli Lilly, AstraZeneca, Sanofi, AbbVie, Regeneron Pharmaceuticals, Gilead Sciences, Takeda Pharmaceutical, Celgene (now part of Bristol-Myers Squibb), GlaxoSmithKline.